Diazinopyrimidines

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof,

wherein

R 1 is hydrogen or alkyl;

R 2 is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl, or —Y 1 —C(O)—Y 2 —R 11 (where Y 1 and Y 2 are independently either absent or an alkylene group and R 11 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino);

R 3 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterosubstituted cycloalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(═O)—R 4 (where R 4 is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino), or acyl;

Ar 1 is aryl;

X 1 is O, NR 5 or S, where R 5 is hydrogen or alkyl; and

X 2 is a bond, O, NR 6 , S or CH 2 , where R 6 is hydrogen or alkyl.

2. The compound according to claim 1 of the formula:

3. The compound according to claim 2 , wherein X 1 is O.

4. The compound according to claim 3 , wherein R 1 is hydrogen.

5. The compound according to claim 4 , wherein R 3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

6. The compound according to claim 5 , wherein R 3 is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

7. The compound according to claim 4 , wherein R 2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.

8. The compound according to claim 7 , wherein R 2 is optionally substituted phenyl.

9. The compound according to claim 8 , wherein R 2 is heterocyclylphenyl, alkylthiophenyl, alkylsulfinylphenyl, alkylsulfonylphenyl, phenyl, halophenyl, hydroxyphenyl, acylphenyl, cyanophenyl, alkoxycarbonylphenyl, carboxamidophenyl, N-alkylcarboxamidophenyl, N,N-dialkylcarboxamidophenyl, alkylsulfonyloxyphenyl, carbamoylphenyl, N-alkylcarbamoylphenyl or N,N-dialkylcarbamoylphenyl.

10. The compound according to claim 9 , wherein R 3 is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

11. The compound according to claim 7 , wherein Ar 1 is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxyphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.

12. The compound according to claim 2 , wherein R 1 is hydrogen.

13. The compound according to claim 12 , wherein R 2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.

14. The compound according to claim 13 , wherein R 3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

15. The compound according to claim 14 , wherein Ar 1 is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxyphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.

16. The compound according to claim 1 , wherein X 2 is a bond or CH 2 .

17. The compound according to claim 16 , wherein R 3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

18. The compound according to claim 17 , wherein R 1 is hydrogen.

19. The compound according to claim 18 , wherein R 2 is heteroalkyl, heterocyclyl, or heterosubstituted cycloalkyl.

20. The compound according to claim 19 , wherein X 1 is O.

21. A composition comprising:

(a) a compound of claim 1 ; and

(b) a pharmaceutically acceptable excipient.

22. A method for treating an FGFR kinase mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of claim 1 , wherein said FGFR kinase mediated disorder comprises atherosclerosis.

23. A method for producing a compound of the formula:

said method comprising the steps of contacting a compound of the formula:

with an amine compound of the formula R 1 R 2 NH to produce a compound of Formula. wherein

R 1 is hydrogen or alkyl;

R 2 is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl or —Y 1 —C(O)—Y 2 —R 11 (where Y 1 and Y 2 are independently either absent or an alkylene group and R 11 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino);

R 3 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(═O)—R 4 (where R 4 is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl;

Ar 1 is aryl;

X 1 is O, NR 5 or S, where R 5 is hydrogen or alkyl;

X 2 is a bond, O, NR 6 , S or CH 2 , where R 6 is hydrogen or alkyl;

n is an integer from 0 to 2; and

R 7 is an alkyl group.

24. The method of claim 23 wherein:

R 1 is hydrogen;

R 2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl;

R 3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl;

Ar 1 is aryl;

X 1 is O;

X 2 is a bond; and

n is 1 or 2.

25. The compound of claim 10 , wherein R 3 is methyl.

26. The compound of claim 25 , wherein R 2 is 4-(morpholin-4-yl)phenyl.

27. The compound of claim 26 , wherein Ar 1 is 2-bromophenyl.

28. The compound of claim 26 , wherein Ar 1 is 2,6-dichlorophenyl.

29. The compound of claim 25 , wherein R 2 is 3-methylsulfinylphenyl.

30. The compound of claim 29 , wherein Ar 1 is 2-bromophenyl.